litlas
Log inCreate account

Balázs Halmos

Active 2002–2026

Also published as
Balazs Halmos
111
Papers
22,427
Citations
58
h-index
103
i10-index

Citations

Citations per year for Balázs Halmos1971: 1 citations1987: 1 citations1988: 1 citations1994: 1 citations2002: 1 citations2003: 7 citations2004: 14 citations2005: 61 citations2006: 132 citations2007: 168 citations2008: 152 citations2009: 142 citations2010: 153 citations2011: 167 citations2012: 156 citations2013: 233 citations2014: 196 citations2015: 214 citations2016: 207 citations2017: 195 citations2018: 206 citations2019: 719 citations2020: 1,087 citations2021: 1,208 citations2022: 865 citations2023: 581 citations2024: 822 citations2025: 393 citations2026: 10 citations1972–1986: no citations, so these years are not shown1989–1993: no citations, so these years are not shown1995–2001: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,936 citing papers, 24.9% of this breakdownChina: 1,671 citing papers, 14.1% of this breakdownJapan: 719 citing papers, 6.1% of this breakdownItaly: 676 citing papers, 5.7% of this breakdownUnited Kingdom: 533 citing papers, 4.5% of this breakdownFrance: 486 citing papers, 4.1% of this breakdownGermany: 465 citing papers, 3.9% of this breakdownSpain: 454 citing papers, 3.8% of this breakdownCanada: 320 citing papers, 2.7% of this breakdownSouth Korea: 317 citing papers, 2.7% of this breakdownSwitzerland: 254 citing papers, 2.2% of this breakdownAustralia: 247 citing papers, 2.1% of this breakdown
0%24.9%Other 23.2%

Institutions

Fields

  • Medicine74.8%
  • Biochemistry, Genetics and Molecular Biology18%
  • Immunology and Microbiology4%
  • Chemistry0.6%
  • Computer Science0.6%
  • Engineering0.4%
  • Other1.6%

Topics

  • Lung Cancer Treatments and Mutations13.6%
  • Cancer Immunotherapy and Biomarkers9.6%
  • Lung Cancer Research Studies6.1%
  • Lung Cancer Diagnosis and Treatment4%
  • Cancer Genomics and Diagnostics3.2%
  • HER2/EGFR in Cancer Research2.3%
  • Other61.2%

Coauthors

All papers

Open in search
  1. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

    Authors: Luis Paz‐Ares, Alexander Luft, David Vicente, Ali Tafreshi, Mahmut Gümüş, Julien Mazières, Bárbara Hermes, Filiz Çay Şenler, Tibor Csőszi, Andrea Fülöp, Jerónimo Rafael Rodríguez‐Cid, Jonathan Wilson, Shunichi Sugawara, Terufumi Kato, Ki Hyeong Lee, Ying Cheng, Silvia Novello, Balázs Halmos, Xiaodong Li, Gregory M. Lubiniecki, Bilal Piperdi, Dariusz M. Kowalski - New England Journal of Medicine 2018 cited by 3,642

  2. Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

    Authors: Silvia Novello, Dariusz M. Kowalski, Alexander Luft, Mahmut Gümüş, David Vicente, Julien Mazières, Jerónimo Rafael Rodríguez‐Cid, Ali Tafreshi, Ying Cheng, Ki Hyeong Lee, Alexander Golf, Shunichi Sugawara, Andrew Robinson, Balázs Halmos, Erin Jensen, Paul Schwarzenberger, M. Catherine Pietanza, Luis Paz‐Ares - Journal of Clinical Oncology 2023 cited by 512

  3. EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

    Authors: Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram, Pasi A. Jänne, Olivier Kocher, Matthew Meyerson, Bruce E. Johnson, Michael J. Eck, Daniel G. Tenen, Balázs Halmos - New England Journal of Medicine 2005 cited by 3,939

  4. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407

    Authors: Luis Paz‐Ares, David Vicente, Ali Tafreshi, Andrew Robinson, Héctor Soto Parrà, Julien Mazières, Bárbara Hermes, İrfan Çiçin, Balazs Medgyasszay, Jerónimo Rafael Rodríguez‐Cid, Isamu Okamoto, Sung-Sook Lee, Rodryg Ramlau, Vladimir Vladimirov, Ying Cheng, Xuan Deng, Ying Zhang, Tuba Öcek Baş, Bilal Piperdi, Balázs Halmos - Journal of Thoracic Oncology 2020 cited by 645

  5. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

    Authors: Zhenfeng Zhang, Jae Cheol Lee, Luping Lin, Victor Olivas, Valerie Au, Thomas LaFramboise, Mohamed Abdel-Rahman, Xiaoqi Wang, Alan D. Levine, Jin Kyung Rho, Yun Jung Choi, Chang‐Min Choi, Sang-We Kim, Se Jin Jang, Young Soo Park, Woo Sung Kim, Dae Ho Lee, Jung‐Shin Lee, Vincent A. Miller, Maria E. Arcila, Marc Ladanyi, Philicia Moonsamy, Charles L. Sawyers, Titus J. Boggon, C. Patrick, Carlota Costa, Miquel Tarón, Rafael Rosell, Balázs Halmos, Trever G. Bivona - Nature Genetics 2012 cited by 1,220

  6. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations

    Authors: Alexa B. Schrock, Garrett M. Frampton, James Suh, Zachary R. Chalmers, Mark R. Rosenzweig, Rachel Erlich, Balázs Halmos, Jonathan W. Goldman, Patrick M. Forde, Kurt Leuenberger, Nir Peled, Gregory P. Kalemkerian, Jeffrey S. Ross, Philip J. Stephens, Vincent A. Miller, Siraj M. Ali, Sai‐Hong Ignatius Ou - Journal of Thoracic Oncology 2016 cited by 381

  7. Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

    Authors: Ryohei Katayama, Alice T. Shaw, Tahsin Khan, Mari Mino–Kenudson, Benjamin Solomon, Balázs Halmos, Nicholas A. Jessop, John C. Wain, Alan T. Yeo, Cyril H. Benes, Lisa Drew, Jamal Saeh, Katherine Crosby, Lecia V. Sequist, A. John Iafrate, Jeffrey A. Engelman - Science Translational Medicine 2012 cited by 1,326

  8. Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3

    Authors: Ishmael Jaiyesimi, Natasha B. Leighl, Nofisat Ismaila, Krishna Alluri, Narjust Florez, Shirish M. Gadgeel, Gregory A. Masters, Erin L. Schenk, Bryan J. Schneider, Lecia V. Sequist, Navneet Singh, Lyudmila Bazhenova, Elizabeth Blanchard, Janet Freeman‐Daily, Naoki Furuya, Balázs Halmos, Ibrahim Azar, Sara Kuruvilla, Michael P. Mullane, Jarushka Naidoo, Joshua E. Reuss, David R. Spigel, Dwight H. Owen, Jyoti D. Patel - Journal of Clinical Oncology 2024 cited by 82

  9. Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3

    Authors: Ishmael Jaiyesimi, Natasha B. Leighl, Nofisat Ismaila, Krishna Alluri, Narjust Florez, Shirish M. Gadgeel, Gregory A. Masters, Erin L. Schenk, Bryan J. Schneider, Lecia V. Sequist, Navneet Singh, Lyudmila Bazhenova, Elizabeth Blanchard, Janet Freeman‐Daily, Naoki Furuya, Balázs Halmos, Ibrahim Azar, Sara Kuruvilla, Michael P. Mullane, Jarushka Naidoo, Joshua E. Reuss, David R. Spigel, Dwight H. Owen, Jyoti D. Patel - Journal of Clinical Oncology 2024 cited by 55

  10. Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)

    Authors: Shirish M. Gadgeel, Nathan A. Pennell, Mary J. Fidler, Balázs Halmos, Philip Bonomi, James Stevenson, Bryan J. Schneider, Ammar Sukari, Jaclyn Ventimiglia, Wei Chen, Cathy Galasso, Antoinette J. Wozniak, Julie L. Boerner, Gregory P. Kalemkerian - Journal of Thoracic Oncology 2018 cited by 224

  11. Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial

    Authors: Luis Paz‐Ares, Yasushi Goto, Wan‐Teck Lim, Balázs Halmos, Byoung Chul Cho, Manuel Cobo, J.L. González-Larriba, Caicun Zhou, Ingel Demedts, Akin Atmaca, Sofia Baka, Bijoyesh Mookerjee, Socorro Portella, Zewen Zhu, Jincheng Wu, David Demanse, Bharani Dharan, Martin Reck - Lung Cancer 2024 cited by 48

  12. Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

    Authors: Marina Chiara Garassino, Shirish M. Gadgeel, Silvia Novello, Balázs Halmos, Enriqueta Felip, Giovanna Speranza, Rina Hui, Edward B. Garon, Hidehito Horinouchi, Shunichi Sugawara, Delvys Rodríguez‐Abreu, Martin Reck, Răzvan Cristescu, Deepti Aurora-Garg, Andrey Loboda, Jared Lunceford, Julie Kobie, Mark Ayers, Bilal Piperdi, M. Catherine Pietanza, Luis Paz‐Ares - JTO Clinical and Research Reports 2022 cited by 42

  13. Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up

    Authors: Shirish M. Gadgeel, Delvys Rodríguez‐Abreu, Balázs Halmos, Marina Chiara Garassino, Takayasu Kurata, Ying Cheng, Erin Jensen, Mark Shamoun, Kumar Rajagopalan, Luis Paz‐Ares - Journal of Thoracic Oncology 2024 cited by 36

  14. Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

    Authors: George N. Naumov, Monique B. Nilsson, Tina Cascone, Alexandra Briggs, Oddbjørn Straume, Lars A. Akslen, Eugene Lifshits, Lauren A. Byers, Li Xu, Hua-Kang Wu, Pasi A. Jänne, Susumu Kobayashi, Balázs Halmos, Daniel G. Tenen, Xiaoou Tang, Jeffrey A. Engelman, Beow Y. Yeap, Judah Folkman, Bruce E. Johnson, John V. Heymach - Clinical Cancer Research 2009 cited by 348

  15. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

    Authors: Hossein Borghaei, Corey J. Langer, Luis Paz‐Ares, Delvys Rodríguez‐Abreu, Balázs Halmos, Marina Chiara Garassino, Baerin Houghton, Takayasu Kurata, Ying Cheng, Jianxin Lin, M. Catherine Pietanza, Bilal Piperdi, Shirish M. Gadgeel - Cancer 2020 cited by 111

  16. Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis

    Authors: Juan Jiang, Yuling Wang, Yang Gao, Haruhiko Sugimura, Fabrizio Minervini, Junji Uchino, Balázs Halmos, Sai Yendamuri, Jeffrey B. Velotta, Min Li - Translational Lung Cancer Research 2022 cited by 72

  17. Selective Personalized RadioImmunotherapy for Locally Advanced Non–Small-Cell Lung Cancer Trial (SPRINT)

    Authors: Nitin Ohri, Shruti Jolly, Benjamin T. Cooper, Rafi Kabarriti, William Bodner, Jonathan Klein, Chandan Guha, V. Shankar, Elaine Shum, Joshua K. Sabari, Haiying Cheng, Rasim Gucalp, Enrico Castellucci, Angel Qin, Shirish M. Gadgeel, Balázs Halmos - Journal of Clinical Oncology 2023 cited by 60

  18. Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study

    Authors: Melissa L. Johnson, James Strauss, Manish R. Patel, Edward B. Garon, Keith D. Eaton, Tavette Neskorik, Josée Morin, Richard C. Chao, Balázs Halmos - Clinical Lung Cancer 2023 cited by 24

  19. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19

    Authors: Michael A. Thompson, Jeffrey P. Henderson, Pankil Shah, Samuel M. Rubinstein, Michael J. Joyner, Toni K. Choueiri, Daniel Flora, Elizabeth A. Griffiths, Anthony P. Gulati, Clara Hwang, Vadim S. Koshkin, Esperanza B. Papadopoulos, Elizabeth Robilotti, Christopher Su, Elizabeth Wulff‐Burchfield, Zhuoer Xie, Peter Paul Yu, Sanjay Mishra, Jonathon W. Senefeld, Dimpy P. Shah, Jeremy L. Warner, Balázs Halmos, Amit Verma, Benjamin A. Gartrell, Sanjay Goel, Nitin Ohri, R. Alejandro Sica, Astha Thakkar, Keith Stockerl‐Goldstein, Omar H. Butt, Jian Campian, Mark A. Fiala, Ryan Monahan, Alice Y. Zhou, Pamela Bohachek, Daniel Mundt, Mitrianna Streckfuss, Eyob Tadesse, Philip E. Lammers, Sanjay G. Revankar, Orestis A. Panagiotou, Pamela Egan, Dimitrios Farmakiotis, Hina Khan, Adam J. Olszewski, Arturo Loaiza‐Bonilla, Salvatore A. Del Prete, Anne H. Angevine, Michael Bär, KM Steve Lo, Jamie Stratton, Paul L. Weinstein, Paolo F. Caimi, Jill S. Barnholtz‐Sloan, Jorge A. García, John Nakayama, Shilpa Gupta, Nathan A. Pennell, Manmeet S. Ahluwalia, Scott J. Dawsey, Amanda Nizam, Christopher A. Lemmon, Claire Hoppenot, Ang Li, Ziad Bakouny, Gabrielle Bouchard, Fiona Busser, Jean M Conners, Catherine Curran, George D. Demetri, Antonio Giordano, Kaitlin M. Kelleher, Anju Nohria, Andrew Schmidt, Grace Shaw, Eliezer M. Van Allen, Pier Vitale Nuzzo, Wenxin Xu, Rebecca L. Zon, Tian Zhang, Susan Halabi, Gary H. Lyman, Jerome Graber, Petros Grivas, Ali Raza Khaki, Elizabeth T. Loggers, Ryan C. Lynch, Elizabeth S. Nakasone, Michael T. Schweizer, Lisa ML Tachiki, Shaveta Vinayak, Michael J. Wagner, Albert C. Yeh, Na Tosha Gatson, Sharad Goyal, Minh‐Phuong Huynh‐Le, Lori J. Rosenstein, Jessica Clément, Ahmad Daher, Mark E. Dailey and 181 more - JAMA Oncology 2021 cited by 185

  20. Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia

    Authors: Mohamed Bentires‐Alj, J. Guillermo Paez, Frank David, Heike Keilhack, Balázs Halmos, Katsuhiko Naoki, John M. Maris, Andrea L. Richardson, Alberto Bardelli, David J. Sugarbaker, William G. Richards, Jinyan Du, Luc Girard, John D. Minna, Mignon L. Loh, David E. Fisher, Victor E. Velculescu, Bert Vogelstein, Matthew Meyerson, William R. Sellers, Benjamin G. Neel - Cancer Research 2004 cited by 513

  21. BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations

    Authors: Daniel B. Costa, Balázs Halmos, Amit Kumar, Susan Schumer, Mark S. Huberman, Titus J. Boggon, Daniel G. Tenen, Susumu Kobayashi - PLoS Medicine 2007 cited by 491

  22. Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations

    Authors: Xuewen Liu, Yuxia Jia, Mark Stoopler, Yufeng Shen, Haiying Cheng, Jinli Chen, Mahesh Mansukhani, Sanjay Koul, Balázs Halmos, Alain Borczuk - Journal of Clinical Oncology 2015 cited by 341

  23. Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer

    Authors: Amit Kumar, Edward T. Petri, Balázs Halmos, Titus J. Boggon - Journal of Clinical Oncology 2008 cited by 308

  24. Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors

    Authors: Jiebai Zhou, Yencheng Chao, Danwei Yao, Ning Ding, Jiamin Li, Lei Gao, Yong Zhang, Xiaobo Xu, Jian Zhou, Balázs Halmos, Nikolaos Tsoukalas, Yuki Kataoka, Ramon Andrade de Mello, Yuanlin Song, Jie Hu - Translational Lung Cancer Research 2021 cited by 56